Leaderboards/Radiopharmaceutical Chemistry and Applications

Radiopharmaceutical Chemistry and Applications

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Xi‐Yang Cui
Chinese Academy of Medical Sciences & Peking Union Medical College
2
Jaleh Fallah
United States Food and Drug Administration
3
Julia Brosch-Lenz
Parents' Place of Maryland
4
Clément Cordier
UCLouvain
5
Gaia Dellepiane
University of Bern
6
Sourav Patra
Bhabha Atomic Research Centre
7
А. V. Nelyubin
NS Kurnakova Institute of General and Inorganic Chemistry
8
Aohan Hu
Cornell University
9
Brooke L. McNeil
TRIUMF
10
Seyedeh Somayyeh Banihashemian
Shahid Beheshti University of Medical Sciences

Papers

1
Covalent targeted radioligands potentiate radionuclide therapy
Nature|2024
165 cit.
2
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
Journal of Clinical Oncology|2024
74 cit.
3
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma
European Journal of Nuclear Medicine and Molecular Imaging|2024
53 cit.
4
[68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET/CT imaging in patients with various type of metastatic cancers
European Journal of Nuclear Medicine and Molecular Imaging|2024
31 cit.
5
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma
Clinical Cancer Research|2024
27 cit.
6
First Experience of Radionuclide Therapy With 177Lu-FAPI-2286 in a Patient With Metastatic Mediastinal Sarcoma
Clinical Nuclear Medicine|2024
23 cit.
7
Publication in Journal of Nuclear Medicine (2024) [23 citations, W4400274721]
Journal of Nuclear Medicine|2024
23 cit.
8
The complete metabolic/molecular response to chemotherapy combined with [177Lu]Lu-FAP-2286 in metastatic breast cancer
European Journal of Nuclear Medicine and Molecular Imaging|2024
15 cit.
9
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis
JNCI Journal of the National Cancer Institute|2024
12 cit.
10
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies
Journal of Clinical Oncology|2024
9 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Justin J. Wilson
Cornell University
2
Alison Y. Zhang
The University of Sydney
3
Zhibo Liu
Beijing National Laboratory for Molecular Sciences
4
Haojun Chen
Wuhan University
5
Eszter Boros
University of Wisconsin–Madison
6
Alexander M. Spokoyny
California NanoSystems Institute
7
Dmitry V. Peryshkov
University of South Carolina Sumter
8
Yangjian Quan
Hong Kong University of Science and Technology
9
Robert R. Flavell
University of California, San Francisco
10
Caterina F. Ramogida
TRIUMF

Papers

1
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
The Lancet Oncology|2022
266 cit.
2
The recovery and separation of lithium by using solvent extraction methods
Coordination Chemistry Reviews|2024
214 cit.
3
Boron encapsulated in a liposome can be used for combinational neutron capture therapy
Nature Communications|2022
122 cit.
4
PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using<sup>68</sup>Ga-FAP-2286: Comparison with<sup>18</sup>F-FDG and<sup>68</sup>Ga-FAPI-46 in a Single-Center, Prospective Study
Journal of Nuclear Medicine|2022
110 cit.
5
Radiotherapy Reduces <i>N</i>-Oxides for Prodrug Activation in Tumors
Journal of the American Chemical Society|2022
104 cit.
6
Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
Journal of Nuclear Medicine|2023
99 cit.
7
Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study
Clinical Cancer Research|2023
93 cit.
8
Advancing Chelation Strategies for Large Metal Ions for Nuclear Medicine Applications
Accounts of Chemical Research|2022
73 cit.
9
Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy
Nature Communications|2023
70 cit.
10
Radiotherapy activates picolinium prodrugs in tumours
Nature Chemistry|2024
70 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
David M. Goldenberg
Unknown
2
Alan J. Welch
University of Arizona
3
Zuowei Xie
Southern University of Science and Technology
4
Michael J. Welch
Geological Survey of Denmark and Greenland
5
Jason S. Lewis
Memorial Sloan Kettering Cancer Center
6
Michael R. Zalutsky
Duke University
7
Ronald W. Davis
Corning (United States)
8
Carolyn J. Anderson
University of Missouri
9
Arul M. Chinnaiyan
Howard Hughes Medical Institute
10
David A. Scheinberg
Memorial Sloan Kettering Cancer Center

Papers

1
Construction of a genetic linkage map in man using restriction fragment length polymorphisms.
PubMed|1980
8.4k cit.
2
Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ
Science|1977
4.7k cit.
3
Functional Characterization of the <i>S. cerevisiae</i> Genome by Gene Deletion and Parallel Analysis
Science|1999
4k cit.
4
Recurrent Fusion of <i>TMPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer
Science|2005
3.9k cit.
5
Integrative Clinical Genomics of Advanced Prostate Cancer
Cell|2015
3.6k cit.
6
A Genome-Wide Transcriptional Analysis of the Mitotic Cell Cycle
Molecular Cell|1998
2.1k cit.
7
Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence
Journal of the American Statistical Association|2005
2k cit.
8
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
Proceedings of the National Academy of Sciences|2003
1.6k cit.
9
Parallel human genome analysis: microarray-based expression monitoring of 1000 genes.
Proceedings of the National Academy of Sciences|1996
1.6k cit.
10
Genome Sequence of an Obligate Intracellular Pathogen of Humans: <i>Chlamydia trachomatis</i>
Science|1998
1.6k cit.

Reagents for Radiopharmaceutical Chemistry and Applications

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

CD44 (8E2) Mouse Monoclonal Antibody

#5640$158,348
View Evidence →
Cell Signaling TechnologyEvidence 61

Cleaved Drosophila Dcp-1 (Asp215) Antibody

#9578$362
View Evidence →
Cell Signaling TechnologyEvidence 64

MERIT40 (D7Y5K) Rabbit Monoclonal Antibody

#12711$161,351
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

Prostate Specific Antigen Membrane Antigen

Cited in 19 papers
#M3620
View Evidence →
Innovative ResearchEvidence 72

Mouse Anti-Human CD1a Monoclonal Antibody, Alexa Fluor 488 Conjugated, Clone 143

Cited in 5 papers
#CD1A20
View Evidence →
Agilent/Dako

Carcinoembryonic Antigen

Cited in 5 papers
#A0115
View Evidence →